超声引导高强度聚焦超声联合促性腺激素释放激素类似物消融T2加权MRI呈均匀高信号的子宫肌瘤
前瞻性研究纳入34例患者42个T2加权MRI呈均匀高信号的症状性子宫肌瘤,18例先接受3个月GnRHa治疗(每月一次)再行HIFU,16例仅行HIFU。联合组治疗时间和辐照时间显著短于单纯HIFU组,治疗效率更高、无灌注体积比更高、能量效应比更低,疼痛评分更低,两组均无显著不良反应;作者认为联合方案可用于消融此类肌瘤。
要点
- T2加权MRI呈均匀高信号的症状性子宫肌瘤,可考虑USgHIFU联合GnRHa消融(作者结论)。
- 联合组治疗时间102.0 min、辐照时间25.4 min,均显著短于单纯HIFU组。
- 联合组无灌注体积比69.2±29.8%,高于单纯HIFU组的50.2±27.3%。
核心结论
- USgHIFU联合GnRHa可用于消融T2加权MRI呈均匀高信号的症状性子宫肌瘤,GnRHa可提高USgHIFU治疗此类肌瘤的有效性,联合治疗可能是子宫肌瘤有前景的替代治疗。
研究设计与样本
- 前瞻性研究,纳入34例患者共42个T2加权MRI呈均匀高信号的症状性子宫肌瘤,多发肌瘤患者仅治疗一个优势肌瘤;按自愿原则18例先行3个月GnRHa治疗(每月一次)再行HIFU,16例仅行HIFU;GnRHa及HIFU前后行增强MRI评估。
关键影像表现/征象
- 联合组治疗时间102.0 min(55.8-152.2 min)、辐照时间25.4 min(12.2-34.1 min),均显著短于单纯USgHIFU组的149.0 min(87.0-210.0 min)和38.9 min(14.0-46.7 min)。
- 联合组治疗效率46.7 mm3 s-1(28.5-95.8 mm3 s-1)、无灌注体积比69.2±29.8%(35.5-97.4%)、能量效应比9.9 KJ mm-3(4.5-15.7 KJ mm-3)。
- 单纯HIFU组治疗效率16.8 mm3 s-1(8.9-32.9 mm3 s-1)、无灌注体积比50.2±27.3%(0-78.6%)、能量效应比23.8 KJ mm-3(12.4-46.2 KJ mm-3),表现为最低治疗效率、最低无灌注体积比和更高能量效应比。
- 联合组疼痛评分3.0±0.5分(2-4分),显著低于单纯USgHIFU组。
- 两组均无显著不良反应。
诊断标准与关键数值
- 以无灌注体积比作为成功消融的指标,联合组69.2±29.8%(35.5-97.4%),单纯HIFU组50.2±27.3%(0-78.6%)。
- 治疗效率联合组46.7 mm3 s-1(28.5-95.8 mm3 s-1) vs 单纯HIFU组16.8 mm3 s-1(8.9-32.9 mm3 s-1)。
- 能量效应比联合组9.9 KJ mm-3(4.5-15.7 KJ mm-3) vs 单纯HIFU组23.8 KJ mm-3(12.4-46.2 KJ mm-3)。
临床应用与阅片要点
- 作者认为USgHIFU联合GnRHa可用于消融T2加权MRI呈均匀高信号的症状性子宫肌瘤。
- 作者指出GnRHa可提高USgHIFU治疗T2加权MRI均匀高信号肌瘤的有效性。
- 作者认为联合治疗可能是子宫肌瘤有前景的替代治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: The study aimed to evaluate the safety and efficiency of ultrasound-guided high-intensity focused ultrasound (USgHIFU) combined with gonadotropin-releasing hormone analogue (GnRHa)-ablating symptomatic uterine leiomyoma with homogeneous hyperintensity on T2 weighted MRI prospectively.
METHODS: A total of 34 patients with 42 symptomatic uterine leiomyomas with homogeneous hyperintensity on T2 weighted MRI were enrolled in our study. In the patient who had multiple uterine leiomyomas, only one dominant leiomyoma was treated. According to the principles of voluntariness, 18 patients underwent a 3-month therapy of GnRHa (once a month) before the high-intensity focused ultrasound (HIFU) treatment, while 16 patients received only HIFU treatment. Enhanced MRI was performed before and after GnRHa and HIFU treatment. Evaluation of the main indicators included treatment time, sonication time, treatment efficiency, non-perfused volume (NPV) (indicative of successful ablation) ratio and energy effect ratio; adverse events were also recorded.
RESULTS: The treatment time and sonication time of the combination group were 102.0 min (55.8-152.2 min) and 25.4 min (12.2-34.1 min); however, they were 149.0 min (87.0-210.0 min) and 38.9 min (14.0-46.7 min) in the simple USgHIFU group. The treatment and sonication time for the combination group was significantly shorter than that for the simple USgHIFU group. Treatment efficiency, NPV ratio and energy effect ratio were 46.7 mm3 s-1 (28.5-95.8 mm3 s-1), 69.2 ± 29.8% (35.5-97.4%) and 9.9 KJ mm-3 (4.5-15.7 KJ mm-3) in the combination group, respectively; but, the lowest treatment efficiency, lowest NPV ratio and more energy effect ratio were observed in the simple HIFU group, which were 16.8 mm3 s-1 (8.9-32.9 mm3 s-1), 50.2 ± 27.3% (0-78.6%) and 23.8 KJ mm-3 (12.4-46.2 KJ mm-3), respectively. Pain scores in the combination group were 3.0 ± 0.5 points (2-4 points)-significantly less than the simple USgHIFU group. There were no significant adverse reactions in either group.
CONCLUSION: Our data suggest that USgHIFU combined with GnRHa may be performed to ablate symptomatic uterine leiomyoma with homogeneous hyperintensity on T2 weighted MRI. Advances in knowledge: The conclusions indicate that GnRHa can improve the effectiveness of the USgHIFU treatment of a homogeneous hyperintense leiomyoma on T2 weighted MRI, and combination treatment could be a promising alternative treatment for the uterine leiomyoma.
引用
- Yang S, Kong F, Hou R, et al. Ultrasound guided high-intensity focused ultrasound combined with gonadotropin releasing hormone analogue (GnRHa) ablating uterine leiomyoma with homogeneous hyperintensity on T2 weighted MR imaging. Br J Radiol. 2017. PMID: 28256923. doi:10.1259/bjr.20160760
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。